Validation, Publication, and Maintenance of real-world data sources and studies in the HMA-EMA RWD Catalogues

The purpose of this SOP is to describe the steps and procedures concerning the validation, publication, and maintenance of data sources and studies within the HMA-EMA Catalogues of real-world data (RWD) sources and studies. The principles and activities described will apply specifically to EMA staff responsible for the validation of the Catalogues’ content. The same principles will apply to the Catalogues’ users when submitting entries.

Year of publication

2025

ISBN

SOP/TDA/3543; EMA/467789/2024

Source

European Medicines Agency (EMA)

Author

European Medicines Agency (EMA)

You might also be interested in

This 2025 country report outlines the policy, research, care and support landscape for rare diseases in France.
ERDERA’s third General Assembly brought partners together in Coimbra to review its second year, strengthen connections across the partnership and align priorities for a more integrated and delivery-focused third year.
ERDERA marked the close of its second year with an Open Session on ultra-rare diseases, bringing together European, regulatory and scientific perspectives on how innovation can reach patients.
December 14 @ 3:00 pm - 4:00 pm
This information webinar on the 2027 Joint Transnational Call for Proposals is scheduled for 14 December 2026.